Furthermore, inhibition of SLC7A11 via genetic or pharmacological targeting attenuates mutant-KRAS associated tumor growth in xenograft models via induction of lipid peroxidation and ferroptosis (56). This evidence concerns the gene SLC7A11 and neoplasm.